{"entity":{"id":"nct07777211","kind":"trial","name":"A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Beijing Gene Key Life Technology Co., Ltd, active and no longer recruiting.","summary":"A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07777211 by Beijing Gene Key Life Technology Co., Ltd, with 52 participants enrolled, started 2025-08-14 and due to reach its primary completion in 2027-03-31. Interventions recorded: GKL-006 injection and Nab-paclitaxel and Gemcitabine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07777211","url":"https://clinicaltrials.gov/study/NCT07777211"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07777211","phase":"1/2","setting":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GKL-006 Injection in Patients With Advanced Pancreatic Cancer","sponsor":"Beijing Gene Key Life Technology Co., Ltd","enrolled":52,"outcomes":[]},"route":"/trials/nct07777211/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"company":[{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","route":"/companies/beijing-gene-key-life-technology/"}]}}